We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Infinity Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products and those under development include therapies targeting hematologic malignancies, or blood cancers; refractory indo... Infinity Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products and those under development include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology-related treatments. The company operates in only one segment which is drug development. Show more
Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology...
Eganelisib Remains Primary Value Driver for Infinity Infinity to Explore Strategic Alternatives to Maximize Value for Stockholders Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | -0.1298 | -80.1234567901 | 0.162 | 0.2597 | 0.0233 | 2541375 | 0.12624096 | CS |
156 | -2.8778 | -98.8934707904 | 2.91 | 3.89 | 0.0233 | 1948842 | 1.7248121 | CS |
260 | -1.5978 | -98.0245398773 | 1.63 | 5.98 | 0.0233 | 1426105 | 2.04316084 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions